

Narnatumab

Cat. No.:	HY-P99375
CAS No.:	1188275-92-4
Target:	Others
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Narnatumab (IMC-RON8) is a neutralizing human monoclonal antibody that blocks RON binding to its ligand, macrophage-stimulating protein (MSP), with a K_d of 32 pM. Narnatumab can be used for the research of cancer ^[1] .								
IC₅₀ & Target	RON(MSPR) ^[1]								
In Vitro	<p>Narnatumab (100 nM; 24 h) inhibits MSP-induced migration of human lung and breast cancer cell lines^[1].</p> <p>Narnatumab inhibits the MSP-induced mitogenic response of a pancreatic cancer cell line^[1].</p> <p>Narnatumab (0.01-100 nM; pretreatment for 1 h) blocks ligand-induced receptor phosphorylation and downstream signaling molecules phosphorylation in RON-expressing tumor cells and in a RON-transfected cell line^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>								
In Vivo	<p>Narnatumab (2-60 mg/kg; i.p. every 3 days) shows antitumor activity in non-small cell lung cancer (NSCLC) and bladder cancer models in athymic mice^[1].</p> <p>Narnatumab exhibits terminal half-life ($t_{1/2}$=5.2 d) and achieves antitumor effects at a steady-state plasma trough level of approximately 140 µg/mL in mice^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Female athymic nu/nu mice (6-8 weeks) were injected NCI-H292 and BFTC-905 cells^[1]</td> </tr> <tr> <td>Dosage:</td> <td>2, 20, 60 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>I.p. every 3 days for 36 and 18 days</td> </tr> <tr> <td>Result:</td> <td>Inhibited tumor growth in a dose-dependent manner.</td> </tr> </table>	Animal Model:	Female athymic nu/nu mice (6-8 weeks) were injected NCI-H292 and BFTC-905 cells ^[1]	Dosage:	2, 20, 60 mg/kg	Administration:	I.p. every 3 days for 36 and 18 days	Result:	Inhibited tumor growth in a dose-dependent manner.
Animal Model:	Female athymic nu/nu mice (6-8 weeks) were injected NCI-H292 and BFTC-905 cells ^[1]								
Dosage:	2, 20, 60 mg/kg								
Administration:	I.p. every 3 days for 36 and 18 days								
Result:	Inhibited tumor growth in a dose-dependent manner.								

REFERENCES

[1]. LoRusso PM, et, al. Phase 1 study of narnatumab, an anti-RON receptor monoclonal antibody, in patients with advanced solid tumors. Invest New Drugs. 2017 Aug;35(4):442-450.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA